Spectral Karyotype (SKY) Analysis of Human Prostate Carcinoma Cell Lines

Prostate

Volumn 57, Issue 3, 2003, Pages 226-244

  Van Bokhoven, Adrie ^a   Caires, Aimee ^a   Di Maria, Michael ^a   Schulte, Aline Passarini ^a   Lucia, M Scott ^a   Nordeen, Steven K ^a   Miller, Gary J ^a   Varella Garcia, Marileila ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Chromosomal abnormalities; Cytogenetics; G banding; Prostate cancer

Indexed keywords

ANDROGEN;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CHROMOSOME 10Q; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 8P; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME G BAND; CHROMOSOME REARRANGEMENT; CHROMOSOME STRUCTURE; CLONAL VARIATION; CONTROLLED STUDY; CYTOGENETICS; HORMONE RESISTANCE; HUMAN; HUMAN CELL; KARYOTYPE; KARYOTYPING; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; SPECTRAL KARYOTYPING;

CARCINOMA; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; HUMANS; MALE; PROSTATIC NEOPLASMS; SPECTRAL KARYOTYPING;

EID: 0142106798     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10291     Document Type: Article

References (44)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer Statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Mitelman F. Recurrent chromosome aberrations in cancer. Mutat Res 2000;462:247-253.
3. Brothman AR, Maxwell TM, Cui J, Deubler DA, Zhu XL. Chromosomal clues to the development of prostate tumors. Prostate 1999;38:303-312.
4. Nupponen N, Visakorpi T. Molecular biology of progression of prostate cancer. Eur Urol 1999;35:351-354.
5. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001;20:173-193.
6. Brothman AR. Cytogenetics and molecular genetics of cancer of the prostate. Am J Med Genet 2002;115:150-156.
7. Ruijter ET, van de Kaa CA, Miller GT, Ruiter DJ, Debruyne FM, Schalken JA. Molecular Genetics and Epidemiology of Prostate Carcinoma. Endocr Rev 1999;22-45.
8. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-225.
9. Mickey DD, Stone KR, Wunderli H, Mickey GH, Vollmer RT, Paulson DF. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res 1977;37:4049-4058.
10. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-281.
11. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. The LNCaP cell line-A new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-132.
12. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
13. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH, Minna JD. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913-2923.
14. Johnson BE, Whang-Peng J, Naylor SL, Zbar B, Brauch H, Lee E, Simmons A, Russell E, Nam MH, Gazdar AF. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J Natl Cancer Inst 1989;81:1223-1228.
15. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
16. Pan Y, Kytola S, Farnebo F, Wang N, Lui WO, Nupponen N, Isola J, Visakorpi T, Bergerheim US, Larsson C. Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet 1999;87:225-232.
17. Pan Y, Lui WO, Nupponen N, Larsson C, Isola J, Visakorpi T, Bergerheim US, Kytola S. 5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines. Genes Chromosomes Cancer 2001;30:187-195.
18. Beheshti B, Karaskova J, Park PC, Squire JA, Beatty BG. Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer cell lines by sequential giemsa banding and spectral karyotyping. Mol Diagn 2000;5:23-32.
19. Varella-Garcia M, Boomer T, Miller GJ. Karyotypic similarity identified by multiplex-FISH relates four prostate adenocarcinoma cell lines: PC-3, PPC-1, ALVA-31, and ALVA-41. Genes Chromosomes Cancer 2001;31:303-315.
20. Aurich-Costa J, Vannier A, Gregoire E, Nowak F, Cherif D. IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: Application to the analysis of seven human prostate cell lines. Genes Chromosomes Cancer 2001;30:143-160.
21. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403-409.
22. Gregory CW, Johnson RT Jr., Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-2898.
23. Lee YG, Korenchuk S, Lehr J, Whitney S, Vessela RA, Pienta KJ. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo 2001;15:157-162.
24. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000;6:1038-1045.
25. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun AS, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-408.
26. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996;93:15152-15157.
27. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997;3:2493-2500.
28. Romijn JC, Erkens-Schulze S, van Weerden WM, Teubel W, Trapman J, Schroder FH. Development and characterization of a new in vitro model to study the mechanisms of prostate cancer progression. Urol Res 1995;23:265.
29. Romijn JC, Erkens-Schulze S, Schroder FH. Perspectives of the use of tissue culture methods as an alternative to human prostate cancer xenografts in nude mice. In: Arnold W, Köpf-Maier P, Michael B, editors. Contributions to oncology: Immunodeficient animals: Models for cancer research. Basel: S. Karger AG; 1996. vol 51, pp 209-213.
30. Korenchuk S, Lehr JE, McLean L, Lee YG, Whitney S, Vessela RA, Lin DL, Pienta KJ. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001;15:163-168.
31. Kim CJ, Kushima R, Okada Y, Seto A. Establishment and characterization of a prostatic small-cell carcinoma cell line (PSK-1) derived from a patient with Klinefelter syndrome. Prostate 2000;42:287-294.
32. van Bokhoven A, Varella-Garcia M, Korch C, Hessels D, Miller GJ. Widely used prostate carcinoma cell lines share common origins. Prostate 2001;47:36-51.
33. van Bokhoven A, Varella-Garcia M, Korch C, Miller GJ. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 2001;61:6340-6344.
34. ISCN. Guidelines for cancer cytogenetics: an international system for human cytogenetics nomenclature (1995). Basel: S. Karger AG; 1995. 114 p.
35. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-3046.
36. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED, Resnick MI, Seftel A, Pretlow TG. CWR22-Androgen -dependent xenograft model derived from a primary human prostatic-carcinoma. Cancer Res 1994;54:6049-6052.
37. Kochera M, Depinet TW, Pretlow TP, Giaconia JM, Edgehouse NL, Pretlow TG, Schwartz S. Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors. Prostate 1999;41:7-11.
38. Laitinen S, Karhu R, Sawyers CL, Vessella RL, Visakorpi T. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chromosomes Cancer 2002;35:66-73.
39. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet 1998;106:105-109.
40. Al Maghrabi J, Vorobyova L, Chapman W, Jewett M, Zielenska M, Squire JA. p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: Analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens. Mod Pathol 2001;14:1252-1262.
41. Mamaeva SE. Karyotypic evolution of cells in culture: A new concept. Int Rev Cytol 1998;178:1-40.
42. Warzynski MJ, Soechtig CE, Maatman TJ, Goldsmith LC, Grobbel MA, Carothers GG, Shockley KF. DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma-necessitating multiple site analysis. Prostate 1995;27:329-335.
43. Zitzelsberger H, Engert D, Walch A, Kulka U, Aubele M, Hofler H, Bauchinger M, Werner M. Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 2001;84:202-208.
44. Okada H, Shirakawa T, Miyake H, Gotoh A, Fujisawa M, Arakawa S, Kamidono S. Establishment of a prostatic small-cell carcinoma cell line (SO-MI). Prostate 2003;56:231-238.